Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries

By afschroeder • November 23, 2025

Bolla E, Semb AG, Petri M, Sfikakis PP, Artim-Esen B, Hernandez-Molina G, Hachulla E, Direskeneli H, Karpouzas GA, Zucchi D, Goyal M, Costedoat-Chalumeau N, Tincani A, Yazici A, Lerang K, Troldborg A, Ajeganova S, Popkova TV, Svenungsson E, Pantazis N, Tektonidou MG; SURF-SLE and APS collaborators. Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries. Lancet Rheumatol. 2025 Nov 19:S2665-9913(25)00257-7. doi: 10.1016/S2665-9913(25)00257-7. Epub ahead of print. PMID: 41274305.

Tags: Harbor UCLA, Publications, Rheumatology

Transferrin Enhances Antifungal Therapy and Improves Survival in Experimental Mucormycosis

Gu Y, Gebremariam T, Ibrahim BA, Harb K, Chan A, Ibrahim AS. Transferrin Enhances Antifungal Therapy and Improves Survival in Experimental Mucormycosis. J Fungi (Basel).[...]

Initial Results Do Not Support That Fully Virtual Pulmonary Rehabilitation Widens Reach to Underserved Patients With COPD

Moy ML, Casaburi R, Nici L. Initial Results Do Not Support That Fully Virtual Pulmonary Rehabilitation Widens Reach to Underserved Patients With COPD. Chronic Obstr[...]

Regulators of Mineralization and Long-Term Progression of Aortic Valve and Mitral Annular Calcification: MESA

Bortnick AE, Naveed M, Fu X, Shea K, Kestenbaum B, de Boer I, Ix JH, Kim R, Hamerton E, Kankaria R, Tracy RP, Tsai M,[...]